Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 10/20 | 0.65 |
| ▸ | INSR | P06213 | 9/20 | 0.65 |
| ▸ | IGF1R | P08069 | 9/20 | 0.65 |
| ▸ | EGFR | P00533 | 10/20 | 0.57 |
| ▸ | MET | P08581 | 1/20 | 0.57 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | ROS1 | P08922 | 1/20 | 0.56 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.52 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25871548 | 0.92 | ALK (0.65) | ALKINSRIGF1REGFRMET | |
| SCHEMBL25872052 | 0.91 | ALK (0.62) | ALKINSRIGF1REGFRMET | |
| SCHEMBL25871927 | 0.90 | ALK (0.62) | ALKINSRIGF1REGFRMET | |
| SCHEMBL25307921 | 0.90 | EGFR (0.71) | ALKINSRIGF1REGFRMET | |
| SCHEMBL25874478 | 0.90 | ALK (0.59) | ALKINSRIGF1REGFR | |
| SCHEMBL25871978 | 0.89 | ALK (0.60) | ALKINSRIGF1REGFRMET | |
| SCHEMBL25871745 | 0.89 | ALK (0.61) | ALKINSRIGF1REGFRMET | |
| SCHEMBL25872849 | 0.88 | ALK (0.59) | ALKINSRIGF1REGFRMET | |
| SCHEMBL25871546 | 0.87 | ALK (0.64) | ALKINSRIGF1REGFR | |
| SCHEMBL25871925 | 0.87 | ALK (0.59) | ALKINSRIGF1REGFRMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4212522-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | J2H Biotech Inc. (KR) | 2023-07-19 | — | — | EP | disclosed |